Nilutamide

Introduction Overview

Generic Name

nilutamide

Brand Name

Nilandron

Dosage Form

oral tablet (150 mg)

Drug Class

Antiandrogens; Hormones / antineoplastics

Pharmacokinetics

Nilutamide is an orally administered non-steroidal antiandrogen primarily used in the treatment of metastatic prostate cancer in men who have undergone surgical castration. It exhibits distinct pharmacokinetic characteristics that influence its clinical efficacy and safety.

Absorption:
Nilutamide is well absorbed when taken orally, with peak plasma concentrations typically achieved within 2 to 4 hours post-dose. The absolute bioavailability is moderately high; however, food intake does not appear to significantly affect its absorption, allowing flexible dosing without regard to meals. The onset of action is rapid enough to provide antiandrogenic effects shortly after administration. Due to consistent absorption, nilutamide maintains stable plasma levels with once-daily dosing despite an initial loading dose.

Distribution:
Following absorption, nilutamide distributes extensively into body tissues, with a volume of distribution reflecting moderate tissue penetration. It exhibits high plasma protein binding, mainly to albumin, which contributes to its sustained presence in circulation and impacts its elimination half-life. The drug crosses various tissue barriers, including prostate cancer metastases sites, enabling targeted receptor antagonism. The relatively large volume of distribution supports adequate systemic exposure to inhibit androgen receptors.

Metabolism:
Nilutamide undergoes hepatic metabolism predominantly via oxidation and conjugation pathways. Cytochrome P450 enzymes, particularly CYP1A2, are implicated in its biotransformation to inactive metabolites. The metabolic process is subject to interindividual variability influenced by genetic polymorphisms and potential drug interactions. Given its hepatic metabolism, liver impairment can significantly affect nilutamide clearance and may necessitate dosage adjustment or avoidance. Metabolites produced do not exhibit significant antiandrogenic activity and are primarily eliminated renally.

Elimination:
Nilutamide and its metabolites are mainly excreted via the urine. The elimination half-life after repeated dosing ranges from approximately 38 to 60 hours, which supports once-daily maintenance dosing following the initial higher loading dose. Prolonged elimination can contribute to accumulation in patients with hepatic dysfunction. Fecal excretion is minimal. In clinical practice, renal impairment does not substantially alter nilutamide clearance. Overall, the elimination profile enables steady drug plasma concentrations conducive to continuous androgen receptor blockade during therapy.

Dosage Forms

Available Dosage Forms:
Nilutamide is commercially available as oral tablets formulated at 150 mg strength. This dosage form facilitates convenient once-daily oral administration and supports consistent plasma drug levels.

Dosages for Adults and Adolescents:
The typical adult dosing regimen for metastatic prostate cancer involves initiating therapy with a loading dose of 300 mg orally once daily for the first 30 days. This loading phase ensures rapid attainment of therapeutic plasma concentrations. After 30 days, the maintenance dose is reduced to 150 mg orally once daily. This dosing strategy is intended for use in combination with surgical castration to maximize clinical efficacy. No specific dosing recommendations are available for adolescents, as the drug is primarily indicated in adult male patients.

Specific Patient Populations:
Nilutamide should be used with caution in patients with pre-existing liver impairment or respiratory conditions due to the risk of hepatotoxicity and pulmonary adverse effects, respectively. Severe hepatic insufficiency and severe breathing problems represent contraindications for nilutamide use. Pharmacokinetic alterations in special populations such as elderly patients do not typically require dose adjustments; however, clinical monitoring is advisable. The drug is not indicated for use in women or pediatric patients, and safety during pregnancy or breastfeeding has not been established.

Mechanism Of Action

Nilutamide is a non-steroidal antiandrogen that exerts its therapeutic effect primarily through competitive inhibition of androgen receptors (AR) in prostate tissue and metastatic cancer cells. By binding to androgen receptors without activating them, nilutamide prevents endogenous androgens, mainly testosterone and dihydrotestosterone, from stimulating AR, thereby suppressing androgen-mediated transcriptional activity essential for prostate cancer cell growth and survival.

At the molecular level, nilutamide's antagonism of the AR blocks the receptor's nuclear translocation and subsequent DNA binding, leading to inhibition of androgen-responsive gene expression. This results in reduced proliferation, induction of apoptosis, and diminished metastatic potential of androgen-dependent prostate cancer cells. Additionally, nilutamide does not inhibit testosterone production directly but complements surgical castration by blocking residual androgen receptor stimulation.

Cellular pathways influenced by nilutamide include downregulation of AR-regulated pathways involved in cell cycle progression and survival signaling. This disruption of androgen signaling cascades leads to decreased tumor growth and progression. Nilutamide's biochemical interactions are highly specific to the AR ligand-binding domain, differentiating it from steroidal antiandrogens and contributing to its favorable safety profile regarding non-androgenic systemic effects.

From a clinical standpoint, nilutamide's mechanism supports its use as an adjunct to orchiectomy (surgical castration) in metastatic prostate cancer, providing an enhanced blockade of androgenic stimulation compared to castration alone. Comparative studies highlight its efficacy in delaying disease progression and improving survival metrics relative to castration monotherapy. The mechanistic insight also underpins its side-effect profile, including effects related to AR blockade in non-target tissues such as the liver and lungs, necessitating vigilant monitoring during therapy.

Pharmacological Actions

Competitive inhibition of androgen receptors, blocking androgen stimulation in prostate cancer cells.
Non-steroidal antiandrogenic activity without intrinsic hormonal agonism.
Suppression of androgen-dependent gene transcription and subsequent cellular proliferation.
Induction of apoptosis and inhibition of metastatic progression in androgen-sensitive tumor cells.
Synergistic effect with surgical castration by preventing receptor activation from residual androgens.
Minimal effect on adrenal androgen pathways, preserving certain hormonal balances.
Liver metabolism leading to inactive metabolites with negligible pharmacological activity.
Potential to cause delayed adaptation in visual dark adjustment due to receptor effects in ocular tissues.
Moderate risk of pulmonary toxicity associated with off-target receptor interactions in lung tissue.
Prolongation of the half-life with sustained plasma concentrations supporting once-daily dosing.
No significant induction or inhibition of cytochrome P450 enzymes, indicating limited drug-drug interaction potential via enzyme modulation.
Minimal androgenic partial agonist activity, differentiating it from steroidal antiandrogens.
Capability to reduce circulating androgen receptor activation even in the presence of low serum androgen levels.
Alters tumor microenvironment by suppressing androgen-responsive stromal cell function.
Inhibits androgen receptor-mediated transcription factors involved in cell survival.

Therapeutic Or Clinical Uses

Treatment of metastatic prostate cancer (Stage D2) in men, specifically those who have undergone surgical castration.
Adjunct therapy combined with orchiectomy to enhance antiandrogenic effects.
Management of advanced androgen-dependent prostate carcinoma to delay tumor progression.
Treatment aimed at reducing the androgen receptor-mediated stimulation of cancer cell growth.
Potential use in patients intolerant or refractory to other forms of hormonal therapy.
Off-label uses may include experimental applications in other androgen-sensitive malignancies.
Alternative antiandrogen therapy when other NSAAs (non-steroidal antiandrogens) are contraindicated or unavailable.
Used to maintain suppression of androgen receptor activation after surgical castration.
Clinical protocols employ nilutamide to prolong survival and improve quality of life in metastatic prostate cancer.
Has a role in multi-modality prostate cancer treatment strategies involving surgical and pharmacologic castration.
May be considered for combination therapy with luteinizing hormone-releasing hormone (LHRH) analogues in certain clinical settings.
Applicable in hormone-sensitive tumors where androgen blockade is critical for disease control.
Used in prostate cancer treatment regimens as recommended by oncology guidelines for metastatic disease.
Supportive therapy to reduce symptoms related to tumor progression mediated by androgens.
Research continues to explore nilutamide’s role in combination with novel agents targeting prostate cancer.

Side Or Adverse Effects

Hot flashes are commonly reported due to androgen deprivation.
Dizziness, which may increase fall risk, especially in elderly patients.
Constipation with variable severity during treatment.
Nausea and vomiting occasionally leading to treatment discontinuation.
Loss of appetite and weight changes related to systemic antiandrogen effects.
Cutaneous reactions including skin rash and pruritus.
Decreased libido and erectile dysfunction, consistent with androgen receptor blockade.
Altered vision, including delayed adaptation to darkness, impairing night vision.
Rare but serious pulmonary toxicity manifesting as cough, dyspnea, and interstitial pneumonitis.
Hepatotoxicity with signs such as nausea, vomiting, right upper quadrant pain, jaundice, elevated liver enzymes.
Potential hypersensitivity reactions including anaphylaxis and angioedema.
Fatigue and general malaise reported during prolonged therapy.
Gynecomastia and breast tenderness in some patients due to hormonal imbalance.
Peripheral edema and fluid retention observed in rare cases.
Occasional laboratory abnormalities including altered liver function tests and hematologic parameters.

Precautions

Use cautiously in patients with pre-existing liver disease; baseline and periodic liver function tests are recommended.
Patients with respiratory disorders such as asthma or chronic lung disease require close monitoring due to risk of pulmonary toxicity.
Nilutamide is contraindicated in individuals with severe hepatic impairment or severe respiratory insufficiency.
Inform patients about the potential for impaired night vision and advise caution when driving or operating machinery in low-light conditions.
Alcohol consumption should be minimized or avoided during treatment to reduce risks of flushing and dizziness.
Monitor for signs of hypersensitivity reactions, particularly on therapy initiation.
Clinical assessment for gastrointestinal tolerance is necessary due to potential for nausea and vomiting.
Consider dose adjustments or discontinuation in case of severe adverse effects or liver toxicity.
Educate patients that nilutamide therapy should not be discontinued abruptly without medical consultation.
This medication is not indicated for use in women; effects during pregnancy and lactation are unknown.
Regular follow-up is essential to assess therapeutic response and detect early adverse reactions.
Inform patients about the importance of adherence to dosing schedules for optimal therapeutic outcomes.
Monitor hormonal and biochemical markers to evaluate efficacy and safety profiles during long-term use.
Evaluate potential drug interactions with concomitant medications including herbal supplements and vitamins.
Advise patients to report any respiratory symptoms such as cough, fever, or shortness of breath promptly.

Warnings

Nilutamide can cause serious lung problems including interstitial pneumonitis, which may present with chest pain, wheezing, dry cough, fever, and worsening shortness of breath.
Severe liver disease is a contraindication due to potential for hepatotoxicity and drug accumulation.
Nilutamide is contraindicated in patients with severe breathing problems or significant pulmonary impairment.
Patients should be monitored closely for signs of allergic reactions, including the development of hives, facial swelling, or difficulty breathing, requiring immediate medical attention.
The drug may cause a delay in the ability to adjust to darkness, increasing risk of accidents during night-time activities.
Abrupt discontinuation of nilutamide may lead to hormonal rebound; therefore, therapy should be tapered or stopped only under medical supervision.
Caution is warranted when used concomitantly with other hepatotoxic agents to avoid compounded liver damage.
Use is not recommended in women, especially during pregnancy or lactation, due to lack of safety data.
Drug interaction potential exists; comprehensive medication reconciliation is necessary before therapy initiation.
Patients with pre-existing cardiac conditions should be monitored for possible exacerbations, although nilutamide’s direct cardiac effects are limited.
Long-term use may require monitoring for secondary malignancies, although evidence remains limited.
Be vigilant for neurotoxic symptoms such as dizziness or visual disturbances as part of adverse effect monitoring.
Discontinue drug immediately if signs of liver dysfunction or severe pulmonary toxicity develop.
Nilutamide may impair wound healing; consider this in perioperative management.
Use caution in elderly patients who may be more susceptible to side effects and toxicities.

Contraindication

Hypersensitivity to nilutamide or any component of the formulation.
Severe liver disease, due to risk of exacerbated hepatotoxicity and impaired drug metabolism.
Severe respiratory disorders including chronic obstructive pulmonary disease with substantial pulmonary compromise.
Women, including pregnant or breastfeeding women, due to unknown safety profile and potential harm.
Patients with known severe pulmonary fibrosis or interstitial lung disease.
Concomitant use of other therapies with high risk of additive pulmonary adverse effects.
Use in pediatric patients is contraindicated as safety and efficacy have not been established.
Patients with acute hepatic failure or progressive liver insufficiency.
Patients with a history of hypersensitivity reactions to other antiandrogens may be contraindicated until evaluated.
Patients with uncontrolled cardiovascular conditions where hypotension or edema might pose additional risk.
Concomitant use with drugs that cause severe hepatotoxicity without rigorous monitoring.
Use in individuals with untreated or unmonitored adrenal insufficiency may be contraindicated.
Contraindicated when surgical castration is not performed or planned, as nilutamide is intended as adjunct therapy.
Avoid use in individuals with severe infections or immune compromise without medical oversight.
Patients with psychiatric illness that may be exacerbated by hormone modulation.

Drug Interactions

Co-administration with hepatotoxic drugs may increase risk of liver injury; liver function must be monitored closely.
Drugs metabolized by CYP1A2 may interact with nilutamide due to shared metabolic pathways, altering plasma levels of either drug.
Concurrent use of warfarin or other anticoagulants warrants caution, as nilutamide may affect coagulation parameters.
Alcohol intake may potentiate adverse effects such as flushing, dizziness, and hypotension.
Interactions with corticosteroids may alter hormonal balance and require dosage adjustments.
Concomitant use of drugs affecting cytochrome P450 enzymes could influence nilutamide metabolism and clearance.
Use with other antiandrogens or hormone therapies requires careful management to avoid additive side effects.
Potential interaction with medications that prolong QT interval, necessitating cardiac monitoring.
Herbal supplements such as St John's Wort may induce metabolic enzymes reducing nilutamide efficacy.
Vitamins and over-the-counter supplements should be disclosed to healthcare providers to avoid unknown interactions.
Phenytoin, carbamazepine, and other enzyme inducers may reduce nilutamide plasma concentrations.
Drugs that cause respiratory depression or bronchospasm should be used cautiously given nilutamide’s pulmonary risk profile.
Monitoring is advised when given with antiemetics or CNS depressants due to additive sedation risk.
Interaction with statins may require lipid monitoring as nilutamide may influence cholesterol metabolism.
No significant interaction with LHRH agonists, often co-administered in prostate cancer treatment.

Preparations Of The Drug

Oral tablets, 150 mg strength, film-coated for ease of swallowing and stability.
Packaged in blister packs or bottles with moisture-resistant properties to maintain drug integrity.
Storage recommendation: room temperature, away from excess moisture and heat, to preserve shelf life.
Available under the brand name Nilandron and generic formulations, with equivalent bioavailability.
Film coating to mask the bitter taste and protect the active pharmaceutical ingredient from degradation.
Standard prescription packaging with patient information leaflets detailing dosage and precautions.
Manufactured according to GMP standards to ensure purity and potency.
Available through specialty oncology pharmacies with dispensing under prescription only.
No currently marketed injectable or alternative dosage forms; oral tablet is sole preparation.
Stable upon exposure to light within packaging; avoid prolonged exposure to open air once blister opened.
Labeling includes clear dosing instructions aligned with oncology therapeutic guidelines.
Bulk packaging available for hospital pharmacy compounding or clinical trial usage.
Standard excipients include fillers, binders, and coatings ensuring consistent dissolution rates.
Counterfeit awareness measures in place due to medical importance and cost considerations.
Limited availability internationally depending on regulatory approval and demand.